Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANTON LEE DUKE

Allopathic & Osteopathic Physicians Pediatrics

NPI
1235108150
CMS profile
853486
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$55.65

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $55.65 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
IRONSHORE PHARMACEUTICALS INC. $55.65 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANTON LEE DUKE

NPI 1235108150 · CMS profile ID 853486

Allopathic & Osteopathic Physicians / Pediatrics

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235108150?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235108150?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235108150?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANTON LEE DUKE, NPI 1235108150, CMS profile ID 853486, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1235108150?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $55.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
IRONSHORE PHARMACEUTICALS INC. $21.1411/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146256139 CMS
IRONSHORE PHARMACEUTICALS INC. $15.3410/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146328221 CMS
IRONSHORE PHARMACEUTICALS INC. $19.1708/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146297770 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $107.73 7
PY2020 $13.83 1
PY2022 $153.22 8
PY2023 $73.99 5
PY2024 $55.65 3
PY2025 $38.48 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $62,873.99 1
PY2025 Principal investigator $4,783.76 5
PY2024 Recipient $266,973.11 1
PY2024 Principal investigator $78,051.13 417
PY2023 Principal investigator $100,958.30 218
PY2022 Principal investigator $51,887.94 40
PY2021 Principal investigator $22,703.72 8
PY2020 Principal investigator $245,184.29 32
PY2019 Principal investigator $95,542.65 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Dermavant Sciences, Inc. $267.75 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434025
Principal investigator 1 Dermavant Sciences, Inc. $267.75 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434027
Principal investigator 1 Dermavant Sciences, Inc. $267.75 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434029
Principal investigator 1 Dermavant Sciences, Inc. $267.75 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434031
Principal investigator 1 Dermavant Sciences, Inc. $1,133.69 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434085
Principal investigator 1 Dermavant Sciences, Inc. $1,063.56 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434087
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434089
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434091
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434093
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434095
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 937434097
Principal investigator 1 Dermavant Sciences, Inc. $190.72 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435355
Principal investigator 1 Dermavant Sciences, Inc. $842.56 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435357
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435359
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435393
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435395
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435397
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435399
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435401
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435403
Principal investigator 1 Dermavant Sciences, Inc. $871.25 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435405
Principal investigator 1 Dermavant Sciences, Inc. $871.25 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435407
Principal investigator 1 Dermavant Sciences, Inc. $871.25 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435409
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435411
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435413
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435415
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435417
Principal investigator 1 Dermavant Sciences, Inc. $1,021.06 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435419
Principal investigator 1 Dermavant Sciences, Inc. $872.31 12/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 937435421
Principal investigator 1 GlaxoSmithKline, LLC. $188.34 12/07/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 965505513
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 10/26/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 950631709
Principal investigator 1 ABBVIE INC. $1,812.50 10/06/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889813557
Principal investigator 1 GlaxoSmithKline, LLC. $1,589.40 09/07/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943933807
Principal investigator 1 GlaxoSmithKline, LLC. $4,930.20 08/12/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943933811
Principal investigator 1 ABBVIE INC. $2,277.50 08/11/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889805705
Principal investigator 1 GlaxoSmithKline, LLC. $1,196.50 07/06/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943933809
Principal investigator 1 GlaxoSmithKline, LLC. $7,635.08 06/17/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943933805
Principal investigator 1 GlaxoSmithKline, LLC. $3,246.56 06/10/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 943933813
Principal investigator 1 ABBVIE INC. $1,812.50 05/05/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889790155
Principal investigator 1 ABBVIE INC. $2,243.75 02/15/2022 Non-covered Recipient Entity
DERMATOLOGY TRIAL ASSOCIATES
A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 889777167